Acadia, page-845

The transcript below is from Acadia and is the basis for the recent Q2 2024 Earnings Report Daybue revenue downgrade:
"Our second quarter recovery in total active patients was driven by a sequential increase in demand and a decrease in numerical discontinuations. First, we generated an increase in new patient starts on DAYBUE, with weekly new starts coming in 12% higher than in the first quarter. At the same time, we experienced a significantly lower rate of weekly discontinuations, decreasing 46% in the second quarter versus the first quarter. While we made important progress on both fronts in the second quarter, our rate of increasing active patients on therapy was slower than anticipated. This is a function of numerical discontinuations decreasing in line with our expectations but our rate of new patient starts while growing total patients on therapy has been slower than projected."
I presume this is English but If I was an Acadia shareholder I would expect something a whole lot clearer.
Kens